Podcasts about sci transl med

Send us a Text Message.Diese Woche besprechen wir die Arbeit von Rahmel et al. zur ketogenen Ernährung in der Sepsis: Rahmel et al. An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis. Sci Transl Med. 16,eadn9285(2024).DOI:10.1126/scitranslmed.adn9285Mit im Studio dabei: Dr. Marie Koch, wissenschaftliche Mitarbeiterin der Klinik fr Anästhesiologie am UKHD. 

In this episode of Discovery Matters, hosts Dodi and Conor explore how synthetic biology can lead to transformative breakthroughs when it comes to dealing with global health problems. Through their conversation with Justin Vigar, a PhD student in Dr. Keith Pardee's lab at the University of Toronto in Canada, we learn how his paper-based diagnostic tool has the potential to provide faster, more cost-efficient, and accessible diagnostics for underserved locations. This is complemented by Amir Pandi and Tobi Erb's discussion of using AI and synthetic biology to develop new antimicrobial peptides. Show notes • U of T PhD student uses synthetic biology to create low-cost diagnostic tools. • Pandi, A., Adam, D., Zare, A. et al. Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides. Nat Commun 14, 7197 (2023). https://doi.org/10.1038/s41467-023-42434-9 • Khalek IS, et al. Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins. Sci Transl Med. 2024 Feb 21;16(735). https://doi.org/10.1126/scitranslmed.adk1867 • Josh A Goldstein, Jason Chao, Shelby Grossman, Alex Stamos, Michael Tomz, How persuasive is AI-generated propaganda?, PNAS Nexus, Volume 3, Issue 2, February 2024. https://doi.org/10.1093/pnasnexus/pgae034

Amaya-Garrido A, et al. Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease. Sci Transl Med. 2023 Sep 6;15(712):eabn5939. doi: 10.1126/scitranslmed.abn5939. Epub 2023 Sep 6. PMID: 37672568.

In this episode, Drs. Lemanne and Gordon discuss research on the role of fasting in the treatment and prevention of cancer.  Dr. Lemanne discusses her personal experience of fasting, and how she uses fasting in the cancer clinic.Exactly when to fast for best cancer outcomeCombining fasting and chemotherapy improves survival--animal studiesTypes of fasts, including water fasts and dry fastsResearch on dry fasting and kidney function (prepare to be surprised)Eating dinner late increases cancer riskDaily intermittent fasting, minimum effective lengthExtended fastsMeth EMS, van Egmond LT, Moulin TC, Cedernaes J, Rosqvist F, Benedict C. Association of Daily Eating Duration and Day-To-Day Variability in the Timing of Eating With Fatal Cancer Risk in Older Men. Front Nutr. 2022 May 10;9:889926. doi: 10.3389/fnut.2022.889926. PMID: 35619965; PMCID: PMC9127957.Links and references of interest:Study evaluating the effect of late dinner on breast and prostate cancer risk Chemotherapy and timing of fasting, University of Southern California studyChemotherapy patients who fast report fewer side effects. Longo group, 2009UCSF fasting page has been taken down. Here is one from City of Hope Cancer Center, in southern California/ greater Los Angeles areaFasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. Longo group, 2012 PMID: 22323820Dawn Lemanne, MD Oregon Integrative OncologyLeave no stone unturned.Deborah Gordon, MDNorthwest Wellness and Memory CenterBuilding Healthy Brains

En el episodio de hoy, hablo de la lesión medular y el entrenamiento con sistemas de soporte de peso corporal, una modalidad de tratamiento que cada vez está más en boga y que parece realmente que tiene su lugar asentado dentro de la rehabilitación de la lesión medular. Normalmente colocamos un arnés al paciente, que se une a una máquina que descarga el peso en un cierto porcentaje. Esa idea se cumple a la perfección en el caso de las grúas pero si pensamos en un paciente que quiere caminar, parece que quitarle peso, no es suficiente. ¿Hay algo más en estos sistemas de soporte de peso? ¿Qué hay de interacción humano-máquina? En este episodio, vemos estudios en sujetos sanos y en lesionados medulares, describimos sistemas de soporte de peso y aportamos ideas prácticas para terapia. Bibliografía: (1)Alexeeva N, Sames C, Jacobs PL, Hobday L, Distasio MM, Mitchell SA, Calancie B. Comparison of training methods to improve walking in persons with chronic spinal cord injury: a randomized clinical trial. J Spinal Cord Med. 2011;34(4):362-79. doi: 10.1179/2045772311Y.0000000018. PMID: 21903010; PMCID: PMC3152808 (https://pubmed.ncbi.nlm.nih.gov/21903010/). (2)Apte S, Plooij M, Vallery H. Influence of body weight unloading on human gait characteristics: a systematic review. J Neuroeng Rehabil. 2018 Jun 20;15(1):53. doi: 10.1186/s12984-018-0380-0. Erratum in: J Neuroeng Rehabil. 2018 Aug 8;15(1):73. PMID: 29925400; PMCID: PMC6011391 (https://pubmed.ncbi.nlm.nih.gov/29925400/). (3)Apte S, Plooij M, Vallery H. Simulation of human gait with body weight support: benchmarking models and unloading strategies. J Neuroeng Rehabil. 2020 Jun 25;17(1):81. doi: 10.1186/s12984-020-00697-z. PMID: 32586398; PMCID: PMC7318415 (https://pubmed.ncbi.nlm.nih.gov/32586398/). (4)Easthope CS, Traini LR, Awai L, Franz M, Rauter G, Curt A, Bolliger M. Overground walking patterns after chronic incomplete spinal cord injury show distinct response patterns to unloading. J Neuroeng Rehabil. 2018 Nov 12;15(1):102. doi: 10.1186/s12984-018-0436-1. PMID: 30419945; PMCID: PMC6233558 (https://pubmed.ncbi.nlm.nih.gov/30419945/). (5)Escribano-Ardura S, Cuesta-Gómez A, Fernández-González P, Carratalá-Tejada M, Molina-Rueda F. Entrenamiento en cinta rodante con soporte parcial del peso corporal en pacientes con lesión medular incompleta: revisión sistemática [Treadmill training with partial body weight support in subjects with incomplete spinal cord injury: a systematic review]. Rev Neurol. 2020 Aug 1;71(3):85-92. Spanish. doi: 10.33588/rn.7103.2020054. PMID: 32672346 (https://pubmed.ncbi.nlm.nih.gov/32672346/). (6)Fenuta AM, Hicks AL. Metabolic demand and muscle activation during different forms of bodyweight supported locomotion in men with incomplete SCI. Biomed Res Int. 2014;2014:632765. doi: 10.1155/2014/632765. Epub 2014 May 21. PMID: 24971340; PMCID: PMC4055602 (https://pubmed.ncbi.nlm.nih.gov/24971340/). (7)Fenuta AM, Hicks AL. Muscle activation during body weight-supported locomotion while using the ZeroG. J Rehabil Res Dev. 2014;51(1):51-8. doi: 10.1682/JRRD.2013.01.0005. PMID: 24805893 (https://pubmed.ncbi.nlm.nih.gov/24805893/9. (8)Fischer AG, Debbi EM, Wolf A. Effects of body weight unloading on electromyographic activity during overground walking. J Electromyogr Kinesiol. 2015 Aug;25(4):709-14. doi: 10.1016/j.jelekin.2015.05.001. Epub 2015 May 16. PMID: 26025610 (https://pubmed.ncbi.nlm.nih.gov/26025610/). (9)Hidler J, Brennan D, Black I, Nichols D, Brady K, Nef T. ZeroG: overground gait and balance training system. J Rehabil Res Dev. 2011;48(4):287-98. doi: 10.1682/jrrd.2010.05.0098. PMID: 21674384 (https://pubmed.ncbi.nlm.nih.gov/21674384/). (10)Huber JP, Sawaki L. Dynamic body-weight support to boost rehabilitation outcomes in patients with non-traumatic spinal cord injury: an observational study. J Neuroeng Rehabil. 2020 Nov 30;17(1):157. doi: 10.1186/s12984-020-00791-2. PMID: 33256797; PMCID: PMC7706039 (https://pubmed.ncbi.nlm.nih.gov/33256797/). (11)Lewek MD. The influence of body weight support on ankle mechanics during treadmill walking. J Biomech. 2011 Jan 4;44(1):128-33. doi: 10.1016/j.jbiomech.2010.08.037. Epub 2010 Sep 19. PMID: 20855074 (https://pubmed.ncbi.nlm.nih.gov/20855074/). (12)Mignardot JB, Le Goff CG, van den Brand R, Capogrosso M, Fumeaux N, Vallery H, Anil S, Lanini J, Fodor I, Eberle G, Ijspeert A, Schurch B, Curt A, Carda S, Bloch J, von Zitzewitz J, Courtine G. A multidirectional gravity-assist algorithm that enhances locomotor control in patients with stroke or spinal cord injury. Sci Transl Med. 2017 Jul 19;9(399):eaah3621. doi: 10.1126/scitranslmed.aah3621. PMID: 28724575 (https://pubmed.ncbi.nlm.nih.gov/28724575/). (13)Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9. PMID: 23850614 (https://pubmed.ncbi.nlm.nih.gov/23850614/). (14)Nooijen CF, Ter Hoeve N, Field-Fote EC. Gait quality is improved by locomotor training in individuals with SCI regardless of training approach. J Neuroeng Rehabil. 2009 Oct 2;6:36. doi: 10.1186/1743-0003-6-36. PMID: 19799783; PMCID: PMC2764722 (https://pubmed.ncbi.nlm.nih.gov/19799783/). (15)M. Plooij, U. Keller, B. Sterke, S. Komi, H. Vallery and J. von Zitzewitz, "Design of RYSEN: An Intrinsically Safe and Low-Power Three-Dimensional Overground Body Weight Support," in IEEE Robotics and Automation Letters, vol. 3, no. 3, pp. 2253-2260, July 2018, doi: 10.1109/LRA.2018.2812913 (https://ieeexplore.ieee.org/document/8307350). (16)Plooij M, Apte S, Keller U, Baines P, Sterke B, Asboth L, Courtine G, von Zitzewitz J, Vallery H. Neglected physical human-robot interaction may explain variable outcomes in gait neurorehabilitation research. Sci Robot. 2021 Sep 22;6(58):eabf1888. doi: 10.1126/scirobotics.abf1888. Epub 2021 Sep 22. PMID: 34550719 (https://pubmed.ncbi.nlm.nih.gov/34550719/). (17)Wessels M, Lucas C, Eriks I, de Groot S. Body weight-supported gait training for restoration of walking in people with an incomplete spinal cord injury: a systematic review. J Rehabil Med. 2010 Jun;42(6):513-9. doi: 10.2340/16501977-0525. PMID: 20549154 (https://pubmed.ncbi.nlm.nih.gov/20549154/).

TWiM discusses antigenic variation within dengue virus serotypes, and an mRNA vaccine that induces antibodies against tick proteins and prevents transmission of the Lyme disease agent. Links Dengue virus antigenic variation (eLife) mRNA vaccine induces tick resistance (Sci Transl Med)

In this episode, I talk with Roy Hamilton, Associate Professor of Neurology at the University of Pennsylvania, about his work using transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (TDCS), and in particular the application of these neuromodulatory techniques to enhance recovery from aphasia.Laboratory for Cognition and Neural StimulationPenn Brain Science, Translation, Innovation, and Modulation CenterHamilton RH, Pascual-Leone A. Cortical plasticity associated with Braille learning. Trends Cogn Sci 1998; 2: 168-174. [doi]Naeser MA, Martin PI, Treglia E, Ho M, Kaplan E, Bashir S, Hamilton R, Coslett HB, Pascual-Leone A. Research with rTMS in the treatment of aphasia. Restor Neurol Neurosci 2010; 28: 511-529. [doi]Hamilton RH, Chrysikou EG, Coslett B. Mechanisms of aphasia recovery after stroke and the role of noninvasive brain stimulation. Brain Lang 2011; 118): 40-50. [doi]Price AR, Peelle JE, Bonner MF, Grossman M, Hamilton RH. Causal evidence for a mechanism of semantic integration in the angular gyrus as revealed by high-definition transcranial direct current stimulation. J Neurosci 2016; 36: 3829-3838. [doi]Carr RM, Lane-Fall MB, South E, Brady D, Momplaisir F, Guerra CE, Montoya-Williams D, Dalembert G, Lavizzo-Mourey R, Hamilton R. Academic careers and the COVID-19 pandemic: Reversing the tide. Sci Transl Med 2021; 13: eabe7189. [doi]

FDA 批准颈动脉窦压力反射刺激疗法治疗心衰Lancet 血ACE2水平与心血管疾病及死亡的关系Science子刊 一种具有几何适应性的人工心脏瓣膜BAROSTIM NEO系统BAROSTIM NEO系统包括一个植入式脉冲发生器（IPG）、一个颈动脉窦含铅套件和一个程序。医生将BAROSTIM NEO脉冲发生器植入晚期心力衰竭患者的左或右锁骨下方，并在患者的左或右颈动脉窦处放置颈动脉窦导线，然后将脉冲发生器连接到颈动脉窦导线上。医生根据病人的个人需求制定脉冲发生器程序，然后向颈动脉的压力感受器传递电脉冲。压力反射激活（BAT）疗法的目的是激活颈动脉壁的压力感受器，刺激自主神经系统的传入和传出神经，大脑接收到神经信号作出相应反应：松弛血管、降低心率、并通过改善肾功能来减少液体储留。2019年8月，FDA批准BAROSTIM NEO系统用于药物治疗无效的、不符合心脏再同步化治疗适应症的、难治性心力衰竭患者。《BeAT-HF研究：这项研究证明了压力反射刺激疗法（BAT）对射血分数降低的心力衰竭患者的安全性和有效性》Journal of American College of Cardiology，2020年7月 (1) BeAT-HF研究是一项多中心、前瞻性、随机对照研究，纳入408名射血分数降低的心力衰竭（HFrEF）患者中，入组要求：纽约心功能分级II-III级、射血分数≤35%、药物治疗方案稳定≥4周、不符合心脏再同步化治疗的I类指征。这篇报告重点汇报了D队列中、NT-proBNP

FDA 批准颈动脉窦压力反射刺激疗法治疗心衰Lancet 血ACE2水平与心血管疾病及死亡的关系Science子刊 一种具有几何适应性的人工心脏瓣膜BAROSTIM NEO系统BAROSTIM NEO系统包括一个植入式脉冲发生器（IPG）、一个颈动脉窦含铅套件和一个程序。医生将BAROSTIM NEO脉冲发生器植入晚期心力衰竭患者的左或右锁骨下方，并在患者的左或右颈动脉窦处放置颈动脉窦导线，然后将脉冲发生器连接到颈动脉窦导线上。医生根据病人的个人需求制定脉冲发生器程序，然后向颈动脉的压力感受器传递电脉冲。压力反射激活（BAT）疗法的目的是激活颈动脉壁的压力感受器，刺激自主神经系统的传入和传出神经，大脑接收到神经信号作出相应反应：松弛血管、降低心率、并通过改善肾功能来减少液体储留。2019年8月，FDA批准BAROSTIM NEO系统用于药物治疗无效的、不符合心脏再同步化治疗适应症的、难治性心力衰竭患者。《BeAT-HF研究：这项研究证明了压力反射刺激疗法（BAT）对射血分数降低的心力衰竭患者的安全性和有效性》Journal of American College of Cardiology，2020年7月 (1) BeAT-HF研究是一项多中心、前瞻性、随机对照研究，纳入408名射血分数降低的心力衰竭（HFrEF）患者中，入组要求：纽约心功能分级II-III级、射血分数≤35%、药物治疗方案稳定≥4周、不符合心脏再同步化治疗的I类指征。这篇报告重点汇报了D队列中、NT-proBNP

FDA 批准2种治疗儿童遗传性癫痫综合征的药物NEJM 早产儿Apgar评分与新生儿死亡风险的关系Science Translational Medicine 基因治疗可逆转Danon病的代谢和多器官功能障碍司替戊醇（Stiripentol）Dravet综合征，以前称为婴儿严重肌阵挛性癫痫，是一种罕见的儿童遗传性癫痫综合征。其典型的特征是药物难治性癫痫发作，抗癫痫药物治疗是主要手段，但总体疗效有限，初始药物选择包括丙戊酸盐、苯二氮卓类药物氯巴占；一线药物治疗失败，也有选择生酮饮食疗法和神经调控技术治疗的。司替戊醇（Stiripentol，CYP450抑制剂，2018年FDA批准用于Dravet综合征的二线治疗，需与丙戊酸盐和氯巴占合用）。《STICLO-France和STICLO-Italy研究：司替戊醇治疗Dravet综合征》Drugs，2019年11月 (1)司替戊醇可以用于氯巴占和丙戊酸盐无法控制的Dravet综合征患者。佐证其疗效的最重要的两个随机对照研究分别为STICLO-France和STICLO-Italy，这两个小型的、随机对照试验，2个月的司替戊醇辅助疗法与明显优于安慰剂，两个研究数据放在一起分析，司替戊醇的缓解率是安慰剂组的10倍（70%比7%）。随后，这些短期结果被扩展为开放标签、观察性研究，当时3-21岁的参与者，长期使用该药物直至中青年，最长服药24年，疗效维持。乏力、食欲减退、体重减轻、共济失调和震颤是最常见的不良事件。结论：根据现有证据，司替戊醇作为Dravet综合征的辅助药物，疗效和安全性均较可靠。芬氟拉明（fenfluramine）2020年6月，芬氟拉明（fenfluramine），是一种安非他明的衍生物，被FDA批准用于治疗≥2岁的Dravet综合征患儿。《FAiRE DS研究：芬氟拉明剂量滴定治疗Dravet综合征的剂量滴定的3期研究》JAMA Neurology，2019年12月 (2)研究旨在评估芬氟拉明治疗司替戊醇治疗效果不佳的、Dravet综合征患者是否可以减少每月惊厥发作频率。这项双盲、安慰剂对照、平行组随机、剂量滴定的3期临床试验，纳入确诊为Dravet综合征的、2岁-18岁的、正在接受稳定剂量司替戊醇治疗的、115名儿童。他们被随机分配到芬氟拉明组和或安慰剂，经过3周的药物滴定后，进入12周的维持治疗。患儿平均年龄9.1岁，惊厥性癫痫发作平均每月25次。12周后，芬氟拉明组的患儿发作频率较安慰剂组下降54.0%；同时，芬氟拉明组54%的患者发作频率下降≥50%，而安慰剂组仅5% (P

FDA 批准2种治疗儿童遗传性癫痫综合征的药物NEJM 早产儿Apgar评分与新生儿死亡风险的关系Science Translational Medicine 基因治疗可逆转Danon病的代谢和多器官功能障碍司替戊醇（Stiripentol）Dravet综合征，以前称为婴儿严重肌阵挛性癫痫，是一种罕见的儿童遗传性癫痫综合征。其典型的特征是药物难治性癫痫发作，抗癫痫药物治疗是主要手段，但总体疗效有限，初始药物选择包括丙戊酸盐、苯二氮卓类药物氯巴占；一线药物治疗失败，也有选择生酮饮食疗法和神经调控技术治疗的。司替戊醇（Stiripentol，CYP450抑制剂，2018年FDA批准用于Dravet综合征的二线治疗，需与丙戊酸盐和氯巴占合用）。《STICLO-France和STICLO-Italy研究：司替戊醇治疗Dravet综合征》Drugs，2019年11月 (1)司替戊醇可以用于氯巴占和丙戊酸盐无法控制的Dravet综合征患者。佐证其疗效的最重要的两个随机对照研究分别为STICLO-France和STICLO-Italy，这两个小型的、随机对照试验，2个月的司替戊醇辅助疗法与明显优于安慰剂，两个研究数据放在一起分析，司替戊醇的缓解率是安慰剂组的10倍（70%比7%）。随后，这些短期结果被扩展为开放标签、观察性研究，当时3-21岁的参与者，长期使用该药物直至中青年，最长服药24年，疗效维持。乏力、食欲减退、体重减轻、共济失调和震颤是最常见的不良事件。结论：根据现有证据，司替戊醇作为Dravet综合征的辅助药物，疗效和安全性均较可靠。芬氟拉明（fenfluramine）2020年6月，芬氟拉明（fenfluramine），是一种安非他明的衍生物，被FDA批准用于治疗≥2岁的Dravet综合征患儿。《FAiRE DS研究：芬氟拉明剂量滴定治疗Dravet综合征的剂量滴定的3期研究》JAMA Neurology，2019年12月 (2)研究旨在评估芬氟拉明治疗司替戊醇治疗效果不佳的、Dravet综合征患者是否可以减少每月惊厥发作频率。这项双盲、安慰剂对照、平行组随机、剂量滴定的3期临床试验，纳入确诊为Dravet综合征的、2岁-18岁的、正在接受稳定剂量司替戊醇治疗的、115名儿童。他们被随机分配到芬氟拉明组和或安慰剂，经过3周的药物滴定后，进入12周的维持治疗。患儿平均年龄9.1岁，惊厥性癫痫发作平均每月25次。12周后，芬氟拉明组的患儿发作频率较安慰剂组下降54.0%；同时，芬氟拉明组54%的患者发作频率下降≥50%，而安慰剂组仅5% (P

Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Chemotherapy Induced Cardiotoxicity? Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians References Scafoglio C, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015 Scafoglio CR,  et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018 Martinez CA, Scafoglio C. Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules. 2020 Paternostro G, Camici PG, Lammerstma AA, Baliga RR, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98(9):2094‐2099. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure [published online ahead of print, 2020 May 6]. JAMA Cardiol. 2020 Fang JC. Heart-Failure Therapy - New Drugs but Old Habits?. N Engl J Med. 2019 McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995‐2008.

This episode: A cancer-killing virus could help increase success of treatment of a form of eye cancer in children! Download Episode (8.0 MB, 8.7 minutes) Show notes: Microbe of the episode: Acanthamoeba polyphaga mimivirus News item Takeaways Cancer obviously is a serious concern, and can be tricky to treat because there are endless varieties in all different places in the body, each of which can have its own expected progression, aggressiveness, and methods of treatment to take into account. Even more serious is when the cancer is in very young children, as is often the case with a cancer of the eye called retinoblastoma. There are about 8000 cases of this disease per year, and when treatment is unsuccessful, it can lead to the loss of one or both eyes. In this study, investigators looked into using a cancer-targeting, oncolytic virus to complement the normal treatment of chemotherapy. The virus for the most part remained localized to the eye where it should be, and targeted the cancer instead of healthy cells, and so seems promising. In the small trial with two patients included in this study, the virus didn't cause a complete recovery, but showed some modest promising results. Journal Paper: Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, De TC, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM. 2019. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med 11:eaat9321. Other interesting stories: Exploring how microbes can influence the flavor of coffee   Email questions or comments to bacteriofiles at gmail dot com. Thanks for listening! Subscribe: Apple Podcasts, RSS, Google Play. Support the show at Patreon, or check out the show at Twitter or Facebook

Chegamos ao terceiro episódio do Podcast Microbiando e nele discutimos um artigo que demonstra como bactérias que vivem na nossa pele podem produzir uma molécula que protege contra o câncer de pele. Esse artigo foi publicado na revista científica Science Advances em fevereiro de 2018 com o título “A commensal strain of Staphylococcus epidermidis protects against skin neoplasia”. No quadro Microlitros de Notícias: uma breve pipetada de novidades da Microbiologia e Imunologia, abordamos os seguintes assuntos: a atividade do leite materno no combate à células tumorais; a utilização de bactérias vampiras contra infecções bacterianas; a descoberta de uma enzima bacteriana capaz de degradar plásticos; e algumas dicas sobre a febre amarela. Na Filogenia da Ciência, iremos trazer a história de um pesquisador muito importante para nós do Instituto de Microbiologia, o professor Paulo de Góes.   Tópicos comentados nesse episódio Microbiota Staphyloccocus epidermidis Atividade antimicrobiana Molécula 6-HAP Fármacos antitumorais Quimioterápico Tumores Prevenção do câncer de pele Leite materno no combate à células tumorais Bactérias vampiras contra infecções bacterianas Enzima bacteriana capaz de degradar plásticos Dicas sobre a febre amarela A vida de Paulo de Góes e do Instituto de Microbiologia/UFRJ   Referências desse episódio Nakatsuji T, Chen TH, Butcher AM, Trzoss LL, Nam SJ, Shirakawa KT, Zhou W, Oh J, Otto M, Fenical W, Gallo RL. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Sci Adv. 2018 Feb 28;4(2) Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, Shafiq F, Kotol PF, Bouslimani A, Melnik AV, Latif H, Kim JN, Lockhart A, Artis K, David G, Taylor P, Streib J, Dorrestein PC, Grier A, Gill SR, Zengler K, Hata TR, Leung DY, Gallo RL. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017 Feb 22;9(378). Plitzko B1, Havemeyer A1, Kunze T1, Clement B2. The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine. J Biol Chem. 2015 Apr 17;290(16):10126-35. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002 Jul;3(7):415-24. Review. James C. S. Ho, Aftab Nadeem e Catharina Svanborg. HAMLET – A protein-lipid complex with broad tumoricidal activity. Biochemical and Biophysical Research Communications. 482: 3, 15 January 2017. Ines Ambite. HAMLET, a new concept for cancer therapy. 2017. Shatzkes, K. et al. Predatory bacteria: a new therapeutic approach for a post-antibiotic era. Future Microbiology. Maio de 2017. Shatzkes, K. et al. Examining the efficacy of intravenous administration of predatory bacteria in rats. Scientific Reports. Maio de 2017. Shatzkes, K. et al. Examining the safety of respiratory and intravenous inoculation of Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus in a mouse model. Nature. Março de 2015. Yoshida et al. A bacterium that degrades and assimilates poly(ethylene terephthalate). Science. Março de 2016 Austin, H. P. et al. Characterization and engineering of a plastic-degrading aromatic polyesterase. PNAS.  Abril de 2018   Sobre o Podcast Microbiando A ideia do Microbiando é discutir artigos científicos de ponta em todas as áreas da microbiologia e imunologia. Vamos utilizar uma linguagem bem acessível para destrinchar esses artigos para vocês, mas sem perder o rigor científico e analítico necessário para essa tarefa. Além de discutir artigos nós teremos o quadro Microlitros de Notícias, onde nossos microbiologistas e imunologistas de plantão irão abordar pequenas reportagens e trazer novidades para vocês. No quadro filogenia da Ciência vamos contar um pouco sobre a vida de grandes personalidades que revolucionar...

Dr. Mark Humayun discusses the results of his team's work on implantation of RPE stems cells placed on a bioengineered surface for dry AMD.  Full reference of the article: Kashani, A. H., Lebkowski, J. S., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Dang, W., . . . Humayun, M. S. (2018). A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med, 10(435). doi:10.1126/scitranslmed.aao4097

Understanding and managing your patient’s pain can be extremely difficult. Liam West spoke to Dr. Tasha Stanton to tap into her vast expertise in the area of pain science. Dr. Stanton is a Senior Research Fellow for the “Body in Mind” group in Australia and has a background in physiotherapy, spinal biomechanics and pain neuroscience. Her work to date has led to several prestigious pain science awards. In this podcast she explains the disconnect between tissue damage and the pain experience, why people experience different levels of pain to the same stimulus and shares how to explain pain to a patient within a clinic setting. Related Articles Discordance between findings on scans (i.e., tissue damage) and pain Hannan MT, Felson DT, and Pincus T. 2000. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatology 27:1513-1517. Brinjikji et al American Journal of Neuroradiology 2015;36:811-16 Central sensitisation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268359/ http://www.noigroup.com/en/Product/EPBII Things that fire together, wire together: http://www.noigroup.com/en/Product/EPSB Explaining the neurobiology of pain: Moseley GL, Butler DS. Fifteen years of Explaining Pain. J Pain. 2015;16:807-13 Our sensations (including pain) are based on the believable, credible evidence that is available to us: Expectations of pain can be important: Bingle et al. Sci Transl Med 2011;3:70ra14 Other sensory input can change pain – the stinky smell study: Bartolo et al PAIN 2013 Our sensations are influence by the meaning that we attach to information: Moseley, Arntz. PAIN 2007;133:64-71 People with chronic pain are not good at learning safety (extinguishing fear to what was painful movement): https://www.ncbi.nlm.nih.gov/pubmed/27776989 A feeling of control and pain: http://psycnet.apa.org/doiLanding?doi=10.1037%2F0033-2909.90.1.89 Associated Podcasts Prof Moseley on the brain and mind in chronic pain - http://bit.ly/1u33pPY Pain coach and first patient contact for pain management - http://bit.ly/2DHCaGa Am I safe to move? Prof Moseley on understanding pain and focusing on the patient - http://bit.ly/2nmCAqu Podcast Quotes “Things that fire together, wire together” “Things that change the ‘need to protect’ your body changes pain”

August 19, 2011 Host Dr. Tim Cripe and co-hosts Dr. Lionel Chow and Dr. Jim Geller discuss updates to previous TWiPO episodes reporting on recent press coverage and publications of BiTE antibodies and modified T-cell approaches, and then discuss recent studies on birth defects, birth order, and cell phone use and possible link to risk of childhood cancers. N Engl J Med. 2011 Aug 10. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. Sci Transl Med 10 August 2011: T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia; Vol. 3, Issue 95, p. 95ra73 7:40 Decitabine upregulation of NY-ESO-1 and MAGE family expression in NB. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic-T lymphocyte-mediated tumor cell killing, K Lucas 9:50 Discussion of Rosenberg paper on immunotherapy in solid tumors; Nat Rev Clin Oncol. 2011 Aug 2. doi: 10.1038/nrclinonc.2011.116. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Rosenberg SA 13:00 Birth anomolies in CNS pediatric tumors 29:00 Absolute risk is small; will this lead to genome-wide association studies? 31:51 Birth order and risk of pediatric cancers 42:30 Mobile phone use and incidence of pediatric CNS tumors. 46:47 Listener question about time elapse of planning clinical trials to opening. Please send any comments or questions to twipo@solvingkidscancer.org

Guest: Paul Martin, PhD, principal investigator, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital Access an abstract of this month’s featured research article: A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med. 2010 Jul 28;2(42):42ra54.

Guest: Paul Martin, PhD, principal investigator, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital Access an abstract of this month’s featured research article: A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med. 2010 Jul 28;2(42):42ra54.

Guest: Jerry Mendell, MD, Nationwide Children's Hospital Access an abstract of this Month's Featured Research Article: Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med 11 November 2009: Vol. 1, Issue 6, p. 6ra15

Guest: Jerry Mendell, MD, Nationwide Children's Hospital Access an abstract of this Month's Featured Research Article: Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med 11 November 2009: Vol. 1, Issue 6, p. 6ra15